Inari Medical Announces Launch of 2021 Ethos and Sustainability Report
May 13 2022 - 4:01PM
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device
company with a mission to treat and transform the lives of patients
suffering from venous and other diseases, announced the publication
of its first ever “Ethos and Sustainability Report.” The report
highlights Inari’s commitment to its ethos, and as part of that to
environmental, social and governance (ESG) leadership. The report
can be found on Inari’s website here.
“I am proud to issue our first annual Ethos and Sustainability
Report as we strive to continue growing and enhancing our ESG
policies and programs,” said Bill Hoffman, Inari Chief Executive
Officer. “In 2021, we invested significant time and resources into
better understanding what drives sustainability at Inari and
exploring how best to present our mission and document our progress
to our stakeholders. We are committed to continual improvement as
responsible corporate citizens with a mission to change the lives
of our patients, and we hope that our 2021 Ethos and Sustainability
Report reflects the responsibility that we feel to this
mission.”
In 2021, Inari undertook its first ESG materiality assessment,
supported by a global, third-party sustainability consultancy, to
identify, prioritize and validate the ESG-related issues most
significant to its business, its stakeholders and the broader
context of the environment and society. The 2021 Ethos and
Sustainability Report was released to inform Inari’s stakeholders
of this progress to date, as well as to communicate our ambitions
going forward.
Inari’s ESG initiatives are overseen by the nominating and
corporate governance committee of the company’s board of
directors.
About Inari Medical, Inc.Inari Medical, Inc. is
a medical device company with a mission to treat and transform the
lives of patients suffering from venous and other diseases. Inari’s
current product offering consists of two minimally invasive, novel
catheter-based mechanical thrombectomy devices that are designed to
remove large clots from large vessels and eliminate the need for
thrombolytic drugs. The company purpose-built its products for the
specific characteristics of the venous system and the treatment of
the two distinct manifestations of venous thromboembolism, or VTE:
deep vein thrombosis and pulmonary embolism. The ClotTriever system
is 510(k)-cleared by FDA and CE marked for the non-surgical removal
of clot from peripheral blood vessels, including for the use in the
treatment of deep vein thrombosis. The FlowTriever system is
510(k)-cleared by FDA and CE marked for the non-surgical removal of
clot from peripheral blood vessels, including for the use in the
treatment of pulmonary embolism and clot in transit in the right
atrium.
Forward Looking StatementsStatements in this
press release may contain “forward-looking statements” that are
subject to substantial risks and uncertainties. Forward-looking
statements contained in this press release may be identified by the
use of words such as “may,” “will,” “should,” “expect,” “plan,”
“anticipate,” “could,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “potential” or
“continue” or the negative of these terms or other similar
expressions, and include, but are not limited to, statements
regarding ESG initiatives, goals and performance. Any
forward-looking statements are based on Inari’s current
expectations, forecasts, and assumptions and are subject to a
number of risks and uncertainties that could cause actual outcomes
and results to differ materially and adversely from those set forth
in or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks and
uncertainties related to market conditions and satisfaction of
customary closing conditions related to the public offering. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled "Risk Factors" in Inari’s most recent Annual Report on
Form 10-K and its other reports filed with the SEC. Forward-looking
statements contained in this announcement are based on information
available to Inari as of the date hereof and are made only as of
the date of this release. Inari undertakes no obligation to update
such information except as required under applicable law. These
forward-looking statements should not be relied upon as
representing Inari’s views as of any date subsequent to the date of
this press release. In light of the foregoing, investors are urged
not to rely on any forward-looking statement in reaching any
conclusion or making any investment decision about any securities
of Inari.
Investor Contact:ICR WestwickeCaroline
CornerPhone +1-415-202-5678 caroline.corner@westwicke.com
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inari Medical (NASDAQ:NARI)
Historical Stock Chart
From Sep 2023 to Sep 2024